Please assess the completion status of the following clinical trial:

Trial Title: Phase I Study of Sulfatinib(HMPL-012) in Patients With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~•≥ 18 and ≤ 70 years of age~* Histological or cytological confirmed solid malignant tumor~* ECOG performance status of 0-2~* Standard regimen failed or no standard regimen available~* Life expectancy of more than 12 weeks~* LVEF ≥ 50%~Exclusion Criteria:~* Pregnant or lactating women~* Adequate hepatic, renal, heart, and hematologic functions (platelets \<75 × 109/L, neutrophil \<1.5 × 109/L, hemoglobin \< 90g/dl ,serum creatinine within upper limit of normal(ULN), total bilirubin and serum transaminase within upper limit of normal(ULN), and PT, APTT, TT, Fbg normal~* Any factors that influence the usage of oral administration~* Evidence of uncontrolled CNS metastasis~* Intercurrence with one of the following: non-controlled hypertension, coronary artery disease, arrhythmia and heart failure~* Abuse of alcohol or drugs~* Less than 4 weeks from the last clinical trial~* Previous treatment with VEGF/VEGFR inhibition~* Disability of serious uncontrolled intercurrence infection~* Uncontrolled hemorrhage in GI~* Within 12 months before the first treatment occurs artery/venous thromboembolic events, such as cerebral vascular accident (including transient ischemic attack) etc.~* Within 6 months before the first treatment occurs acute myocardial infarction, acute coronary syndrome or CABG~* Bone fracture or wounds that was not cured for a long time~* Coagulation dysfunction, hemorrhagic tendency or receiving anticoagulant therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Sulfatinib capsule (Type: EXPERIMENTAL): cohort 1: Sulfatinib single oral dosing;after 7days,Sulfatinib continuous oral dosing ( once a day) 28days as a cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).